TORNTPHARM

– Niche Momentum

While bigger pharma names fight over generics,

's found its sweet spot in chronic diseases - diabetes, heart conditions, the stuff people need forever. And it's paying off. India business up 14.5% (that's solid in today's market) Germany absolutely flying at 21% growth R&D spending up 6% - they're actually investing in the future They're not trying to be everything to everyone. Instead of chasing every generic opportunity, they're doubling down on areas where they can actually differentiate and build lasting relationships with doctors. The reality check: US pricing is still brutal (welcome to pharma), but they're holding their ground while others get hammered. Brazil's stable, which honestly counts as a win these days. In a commodity business, being the go-to player in specific therapeutic areas is gold. When a doctor trusts your diabetes portfolio, they're not switching for a 5% price difference. The real test is whether they can keep this momentum as competition inevitably shows up in their niches. But right now, Torrent looks like they've cracked the code on sustainable pharma growth - focus beats scale every time.